circadian rhythm raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-24. Anything still debated is marked as such rather than presented as settled.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
dadantii must overcome obstacles, such as defense barriers, secondary metabolites and toxic materials. An example of a plant defense mechanism is to produce a defensive barrier, such as a cork layer. However, when the infection is spread by larvae, the cork layer is eaten as quickly as it is made by the plant. Consequently, the protective cork layer is an ineffective protection mechanism. The bacteria continue to spread and multiply throughout the plant, moving in the intercellular spaces, within collapsed cells and the xylem. As the bacteria grow in numbers, additional hosts are infected through the spread of bacteria by: splashing water from infected plants, insects, and cultural practices including the use of contaminated tools, gloves and machinery and improper storage of cultivated crops or seeds. D. dadantii can be a problem year round, given the right environmental conditions exist. It is able to infect plants in greenhouses, indoor interiorscapes and tropical areas where temperatures and humidity remains high. At higher latitudes, infections are mainly during the hot and humid summer months.
On November 28, 2025, The Washington Post published an article alleging Hegseth had given a spoken order to kill the survivors of a September 2, 2025, strike led by SEAL Team 6 on a boat suspected of carrying drugs in the Caribbean Sea. The operation was overseen by Admiral Frank M. "Mitch" Bradley, from Fort Bragg in North Carolina. Bradley described the survivors as legitimate targets, as they could theoretically have contacted other traffickers to rescue them and their cargo, and subsequently ordered the second strike to complete Hegseth's order that everyone must be killed. Hegseth's explanation for the strike has shifted over time. The Office of Legal Counsel eventually argued that the strike was legal because its goal was to destroy the boat, not to kill the crew, reflecting a secret legal memo endorsing such strikes; the memo has been "fiercely criticized" by legal experts. The strike was the first in a series of strikes against suspected drug traffickers. Hegseth's alleged orders were characterized by several legal experts as murder and a war crime. The alleged orders were condemned by members of congress, including Representative Seth Moulton, who said "Mark my words: It may take some time, but Americans will be prosecuted for this, either as a war crime or outright murder." Both Senators Tim Kaine and Mark Kelly described the alleged orders as a war crime.
==== Earl G. Graves School of Business and Management ==== The Earl G. Graves School of Business and Management (GSBM) is named in honor of alumnus Earl G. Graves, Sr. and is housed in the Graves School of Business and Management building, which was opened for the Fall Semester 2015 at the western edge of the campus. It contains classrooms, laboratories, and office buildings with rooms for hospitality management students to operate. The GSBM offers Bachelor of Science, Master of Science, Master of Business Administration, and PhD degree programs. These programs are accredited by The Association to Advance Collegiate Schools of Business (AACSB).
==== Chemically reactive agents ==== Agents such as hydrogen peroxide, elemental chlorine, hypochlorous acid (chlorine water), bromine, bromine water, iodine, nitric and oxidising acids, and ozone react with sensitive moieties such as sulfide/thiol, activated aromatic rings (phenylalanine) in effect damage the protein and render it useless.
==== Phenibut ==== Phenibut (Anvifen, Fenibut, Noofen) is an anxiolytic used in Russia. Phenibut is a GABAB receptor agonist, as well as an antagonist at α2δ subunit-containing voltage-dependent calcium channels (VDCCs), similarly to gabapentinoids like gabapentin and pregabalin. The medication is not approved by the FDA for use in the United States, but is sold online as a supplement.
Sources: en.wikipedia.org
=== South Sudan === South Sudan has large oil reserves, but most of it is exported and it relies on imports for refined products. Because the country generates 96% of its electricity from oil, the government has started rationing electricity in the capital, Juba, which affects businesses, and rolling power cuts are expected to continue.
The team of inventors Edison employed at his laboratories in Menlo Park, New Jersey did, however, develop the first practical light bulb in 1880 (employing a carbonized bamboo filament), shortly prior to Joseph Swan, who invented an even more efficient bulb in 1881 (which used a cellulose filament). Henry Ford did not invent either the automobile or the assembly line. He did improve the assembly line process substantially, sometimes through his own engineering but more often through sponsoring the work of his employees, and he was the main person behind the introduction of the Model T, regarded as the first affordable automobile. Karl Benz (co-founder of Mercedes-Benz) is credited with the invention of the first modern automobile, and the assembly line has existed throughout history. Al Gore never said that he had "invented" the Internet. What Gore actually said was, "During my service in the United States Congress, I took the initiative in creating the Internet", in reference to his political work towards developing the Internet for widespread public use. Gore was the original drafter of the High Performance Computing and Communication Act of 1991, which provided significant funding for supercomputing centers, and this in turn led to upgrades of a major part of the already-existing early 1990s Internet backbone, the NSFNet, and development of NCSA Mosaic, the browser that popularized the World Wide Web.
=== Persistent viruses === Using quantitative polymerase chain reaction (qPCR) and next-generation sequencing (NGS) a maximum of five DNA viruses per individual have been identified. Included were several herpesviruses, hepatitis B virus, Merkel cell polyomavirus, and human papillomavirus 31. Given the reactivation and/or oncogenic potential of these viruses, their repercussion on hematopoietic and malignant disorders calls for further studies.
==== Ligand exchange ==== Post-synthetic modification techniques can be used to exchange an existing organic linking group in a prefabricated MOF with a new linker by ligand exchange or partial ligand exchange. This exchange allows for the pores and, in some cases the overall framework of MOFs, to be tailored for specific purposes. Some of these uses include fine-tuning the material for selective adsorption, gas storage, and catalysis. To perform ligand exchange prefabricated MOF crystals are washed with solvent and then soaked in a solution of the new linker. The exchange often requires heat and occurs on the time scale of a few days. Post-synthetic ligand exchange also enables the incorporation of functional groups into MOFs that otherwise would not survive MOF synthesis, due to temperature, pH, or other reaction conditions, or hinder the synthesis itself by competition with donor groups on the loaning ligand.
The Ten Years' War ended in 1878, and the Spanish government authorized the creation of political parties in Cuba. Most of the leadership of the Grand Lodge of Colon at Havana were founding members of the Autonomist Liberal Party. Antonio Govín y Torres himself became the Secretary of the Autonomist Liberal Party. José María Gálvez became the Party President. Rafael Montoro, the intellectual leader of the party, also served as the Worshipful Master of Logia Plus Ultra (English: Plus Ultra Lodge). Other Freemasons became founding members of the Moderate Party of Cuba. On October 8, 1878, discussions opened on merging the Lodges of Colon Freemasonry and Cuban Freemasonry into a new unified body. The Little War occurred from 1879 to 1880. On either January 25, 1880 or March 25, 1880, the Grand Lodge of Colon at Havana and the Grand Lodge of Cuba, and 46 of their Lodges, merged to become the Gran Logia Unida de Colón y la Isla de Cuba (English United Grand Lodge of Colon and the Island of Cuba). After decades of multiple Grand Lodges and Grand Orients on the island, there was now a single and unified Grand Loge for the entire island of Cuba, with one Grand Master and two Deputy Grand Masters. The United Grand Lodge gained recognition from 34 foreign Masonic bodies. On September 4, 1881, 25 Lodges in Camagüey Province and Oriente Province accepted the authority and joined the United Grand Lodge. In 1881, seventy-one lodges operated in Cuba under the authority of the Grand Lodge.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.